This is just the beginning! Our collection holds over 300 years of history, including rare newspapers, obituaries, marriage records, birth records, and so much more—most of which you won’t find anywhere else!
Government study finds raloxifene as safe as tamoxifen for high risk women
An $88 million trial showed raloxifene and tamoxifen similarly reduce serious breast cancers in nearly 20 000 postmenopausal women at high risk. Yet raloxifene users had fewer uterine cancers and blood clots, though uterine results were not statistically significant, raising debate over a clear winner.
MENTIONED IN THIS ARTICLE
National Cancer Institute
Len Lichtenfeld
American Cancer Society
American Society of Clinical Oncology
The
Cancer Institute
Laos
Eli Lilly & Co
Journal of the American Medical Association
Joseph Costantino
University of the the
Cancer Society
Lichtenfeld
George Somio
City of Hope Cancer Center
Duarte
Calif
Ford
Price
Lilly
Evista
Food and Drug Administration